Nanoparticle Nasal Spray Delivers Oxytocin Directly to the Brain in Mice

Researchers used a Design of Experiments (DoE) statistical approach to optimize PLGA nanoparticle formulations loaded with oxytocin. They created both standard (OT-NP) and PEGylated (OT-NP-PEG) versions, characterizing particle size, stability, and release kinetics. They synthesized radioactively labeled [14C] oxytocin to track biodistribution after intranasal administration in mice, measuring uptake in the brain (olfactory bulb, frontal cortex), blood, and liver. Behavioral effects were assessed by measuring self-grooming frequency.

Oxytocin is being explored as a treatment for autism spectrum disorder, but nasal sprays deliver it inconsistently to the brain, with much of the peptide ending up in the bloodstream instead. This nanoparticle system could solve that problem by protecting oxytocin and routing it directly through the nose-to-brain pathway, potentially making oxytocin therapy more effective and reducing side effects.

Nose-to-brain delivery is one of the most active frontiers in peptide drug delivery, offering a way to bypass the blood-brain barrier entirely. This study demonstrates that rationally designed nanoparticles can successfully deliver a peptide to specific brain regions via the nasal route — a platform approach that could eventually be applied not just to oxytocin but to other neuropeptides for conditions like depression, PTSD, and neurodegeneration.

This is a preclinical mouse study — nose-to-brain delivery may differ significantly in humans due to anatomical differences. The behavioral endpoint (self-grooming) is a crude proxy for the social behavior effects sought in ASD treatment. No toxicity data or long-term safety assessment is reported. The transition from mice to human clinical use involves substantial formulation and regulatory hurdles.